|Assessment Status||Rapid review complete|
|Indication||For the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.|
|Rapid review commissioned||06/06/2013|
|Rapid review completed||03/07/2013|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.